Search

The High-Granularity Timing Detector is a detector proposed for the ATLAS Phase II upgrade. The detector, based on the Low-Gain Avalanche Detector (LGAD) technology will cover the pseudo-rapidity region of $2.4, Comment: 17 pages, 20 figures

Accelerometers are widely used in inertial navigation systems, and its performance will limit the accuracy level of navigation. As one of the key factors, nonlinearity degrades the dynamic performance of the accelerometer, especially when it is used in vibrational environment. This paper presents a model of nonlinearity analysis for closed-loop micro-silicon accelerometer, and the deviation of the proof mass from its rest position is considered as the main source of nonlinearity, which is mainly caused by electronic offset of the detector diodes circuit. Based on this model, the relationship between the proof mass position and electronic offset is deduced, and the equation for the feedback voltage, input acceleration and the proof mass position deviation is also derived, which provides the foundation for nonlinearity analysis. In order to improve the linearity of the accelerometer, the electronic offset is decreased by debugging the circuit parameters, so that the proof mass can work in its rest position. And the test results with centrifuge show that the nonlinearity of the accelerometer can be decreased at least by one order of magnitude.

Introduction Upper urinary tract urothelial carcinoma (UTUC) in Taiwan is a relatively high prevalent cancer and locally advanced UTUC often carries a poor prognosis. This study is to analyse role of SPARCL1 in UTUC of Taiwan and analyse if there were any association between SPARCL1 presentation and clinical oncologic outcome. Material and methods We initially got fresh frozen cancer tissue from three high grade locally advanced UTUC (stage >2) and three fresh frozen normal urothelium tissue from low grade and stage 0 disease in Kaohsiung Chang Gung Memorial Hospital. In this study, we used DNA methylation assay and SPARCL1 was identified as most significant different DNA methylation in locally advanced cancer compared with normal urothelium tissue. From 2005 to 2012, this study included 78 patients with pT3N0M0 UTUC. Perioperative factors, pathological features, and SPARCL1 immunostaining were reviewed and prognostic factors were examined by multivariate analysis. Cell line study with BFTC909 and BFTC909-SPARCL1 overexpression was used for cancer behaviour observation. The sensitivity of both cell line to cisplatin and radiation was tested. Results and discussions SPARCL1 was revealed as 20 fold change of methylation in locally advanced UTUC compared with normal urothelium. The patient demography revealed that all pT3N0M0 patient is each group have similar clinical and pathological factors. Systemic UTUC recurrence was significant more in UTUC with negative SPARCL1 presentation (p=0.042). Multivariate analysis found that negative SPARCL1 and non-papillary tumour architexture were the two significant prognostic factors associated with systemic UTUC recurrence (p=0.011 and 0.008 respectively). Cell line study revealed that BFTC 909-SPARCL1 overexpression is associated with less aggressive cancer cell migration/invasion and more sensitivity to cisplatin or radiation treatment. Conclusion SPARCL1 is the most significant methylated gene in locally advanced tissue compared with normal urothelium. For those patients with pT3N0M0 UTUC, SPARCL1 is an independent prognostic marker. The presence of SPARCL1 interferes with UTUC cell line behaviour and sensitivity to cisplatin or radiation.

Sample-to-answer devices that both amplify and detect nucleic acid targets will find use in health-care, agricultural, forensic medicine, military applications, environmental monitoring and animal husbandry. Ideally, these devices will be able to start with almost any sample input, be inexpensive to manufacture, utilize portable instrumentation, and require no user intervention. In practice, developing devices that meet these criteria are difficult due to limitations imposed by the enzymatic amplification procedures, and the DNA detection platform. Motorola's Clinical Micro Sensors division has recently developed and commercialized an electronic nucleic acid detection platform that simplifies the process for building sample-to-answer devices.